Global DNA-encoded Library Market Revenue Grows at a CAGR of 13.32%.

Introduction

Straits Research released its highly anticipated report, “Global DNA-encoded Library Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 851.06 million in 2025 and is projected to expand to USD 2,613.81 billion by 2034, registering a compound annual growth rate (CAGR) of 13.32%.

Market Dynamics

The global DNA‑encoded library market is witnessing robust growth, driven by the increasing demand for efficient and high-throughput drug discovery solutions. DNA encoded libraries allow simultaneous screening of billions of compounds through unique DNA barcoding, accelerating hit identification and lead discovery compared with traditional methods. This capability has become particularly valuable for pharmaceutical and biotechnology companies under pressure to bring novel therapies to market faster and more cost-effectively.

However, the market faces certain restraints, with technical and infrastructural complexities being a challenge. Creating, screening, and decoding large DELs requires advanced DNA synthesis and sequencing technologies, sophisticated bioinformatics pipelines, and specialized expertise in chemistry and molecular biology. Such high entry barriers limit adoption among smaller biotech firms and academic institutions, slowing broader market penetration.

On the other hand, substantial opportunities exist through the integration of DEL platforms with emerging trends such as personalized medicine, AI-driven drug design, and expanding therapeutic areas beyond traditional targets. As drug developers increasingly focus on highly selective, patient-specific therapies in complex areas like oncology, neurological disorders, and rare diseases, DEL technology provides a scalable and versatile foundation, thereby supporting market growth.

Market Highlights

• Product & Service: The product segment is expected to register the fastest CAGR of 14.03%. 
• Therapeutic Area: The oncology segment dominated the market with a revenue share of 37.21% in 2025.
• Application: The hit generation/identification segment dominated the market with a revenue share of 42.47%.
• End User: The pharmaceutical & biotechnology companies segment dominated the market in 2025. 
• Regional Insights: North America dominated the market, accounting for 44.62% share in 2025, owing to the presence of a large number of pharmaceutical and biotechnology companies actively investing in advanced drug discovery technologies.

Competitive Players

1. Aurigene Pharmaceutical Services Ltd.
2. BioDuro
3. BOC Sciences
4. Charles River Laboratories International, Inc.
5. Creative Diagnostics
6. DyNAbind GmbH
7. GenScript
8. HitGen Ltd.
9. LGC Bioresearch Technologies
10. Life Chemicals Inc.
11. Merck KGaA
12. Pharmaron
13. Philochem AG
14. SPT Labtech Ltd
15. Vipergen ApS
16. WuXi AppTec Co., Ltd.
17. Others

Recent Developments

April 2024: Vipergen partnered with Aurigene Pharmaceutical Services to enhance drug discovery, combining DEL technology for screening over a billion compounds and co-developing libraries with greater chemical diversity and drug-likeness.

Segmentation

1. By Product & Service (2026-2034)
   1. Product
      1. Kits & Reagents
      2. Encoded Libraries
      3. Others
   2. Services
      1. Design & Synthesis Services
      2. Screening Services
      3. Others
2. By Therapeutic Area (2026-2034)
   1. Oncology
   2. Infectious Diseases
   3. Cardiovascular Diseases
   4. Neurological Diseases
   5. Autoimmune Diseases
   6. Metabolic Diseases
   7. Others
3. By Application (2026-2034)
   1. Hit Generation / Identification
   2. Hit to Lead
   3. Hit Validation / Optimization
   4. Others
4. By End Use (2026-2034)
   1. Pharmaceutical & Biotechnology Companies
   2. Contract Research Organizations
   3. Academic & Research Institutes
   4. Others